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Background. Arthritis is a common condition that co-exists in the elderly population. This condition leads to frequent
administration of comorbid analgesics especially non steroidal anti-inﬂammatory drugs (NSAIDs). Aim. To study cardiorenal
toxicity of celecoxib versus ibuprofen in arthritic patients. Subjects and Methods. Seven hundred ninety-wo arthritic patients
were enrolled in the study for 6 months. Three hundred ninety-six patients administered celecoxib 400mg twice a day; 396
patients administered ibuprofen 300mg three times a day. Eﬀects measured included investigator-reported hypertension, edema,
or congestive heart failure, increases in serum creatinine or reduction in serum creatinine clearance, and changes in serum
electrolytes. Results. Celecoxib wasassociated with signiﬁcant(P<. 05) lowerincidence ofhypertension and edema incomparison
with ibuprofen. Systolic hypertension occurred signiﬁcantly less (P<. 05) with celecoxib compared with ibuprofen. Serum
creatinine was signiﬁcantly increased (P<. 05) in patients treated with ibuprofen in comparison with celecoxib. Creatinine
clearance was signiﬁcantly lower (P<. 05) in cases treated with ibuprofen in comparison to celecoxib. Nonsigniﬁcant changes in
serum body electrolytes occurred. Conclusion. The most important ﬁnding of this study was the lowering incidence of cardiorenal
toxicity of celecoxib in comparison with ibuprofen.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs, NSAIDs are widely
used drugs valued for their anti-inﬂammatory, analgesic
and antipyretic properties. However, Classic (nonselective,)
NSAIDs work by inhibiting two isoforms of the enzyme
Cyclo-oxygenase (COX): COX-1 and COX-2. COX-1 is ex-
pressed continuously in most body tissues and in the stom-
ach catalyses the production of prostaglandins which safe-
guard the gastric mucosa. Inhibition ofCOX-1 is responsible
for NSAID-induced gastrointestinal damage [1]. COX-2 is
much less widely expressed but is induced by proinﬂam-
matory stimuli and catalyses prostaglandins mediating the
inﬂammatory response. Anti-inﬂammatory action is derived
from inhibition of COX-2 [2].
It is believed that selective COX-2 inhibitors (COXIBs)
have reduced side eﬀects especially gastrointestinal and
platelet-related adverse events in comparison to classic
NSAIDs. Celecoxib was the ﬁrst COX-2 selective inhibitors
tobedeveloped.Atfulltherapeuticdoses,celecoxibpossesses
comparableanalgesicand inﬂammatory eﬃcacytononselec-
tive NSAIDs in the treatment of rheumatoid arthritis (RA)
and osteoarthritis (OA) [3–5].
Non-selective inhibition of prostaglandins synthesis is
associated with antinatriuretic and vasoconstrictor eﬀects
and frequently reduces glomerular ﬁltration rate (GFR). The
sensing mechanisms of sodium are largely through the
COX-2 enzymatic pathway located in the macula densa
of the kidney. The inhibition of this enzyme will lead to
antinatriuretic eﬀect that is manifested clinically by edema,
and frequently linked with, destabilization of blood pressure2 Journal of Toxicology
(BP) control in treated hypertensive individuals. In addition,
itmaysubsequentlyinducecongestiveheartfailureinsuscep-
tibleindividual,sotheuseofnonselectiveNSAIDsmayresult
in acute hemodynamically mediated deterioration of renal
functions in one of ﬁve patients within several days of
NSAIDs use. This is fully reversible following discontinua-
tion of the oﬀending drug. Other syndromes are extremely
rare; they include other electrolyte complications such as
hyperkalemia, and hyponatremia, nephritic syndrome with
interstitial nephritis [6, 7].
On the other hand, the use of selective COX-2 in healthy
individualsis associated with mild oedema and hypertension
due to modest sodium retention in the ﬁrst one to two days
of therapy. It is followed by a return to baseline excretion
levelsandelimination ofretainedsaltandwaterafteranother
one to two days without drug discontinuation. It may be
hypothesized that a selective COX-2 inhibitors (celecoxib)
may have decreased renal adverse eﬀects relative to non-
selective inhibitors [8, 9].
The celecoxib long-term arthritis safety study (CLASS)
was undertaken to compare the long term upper gastroin-
testinal tract of celecoxib 400mg twice daily (b.i.d.) two
to four times the full therapeutic doses for RA and OA,
respectively, with normal full therapeutic doses of one of
classic NSAIDs, for example, ibuprofen 800mg three times
a day (t.d.s.). The CLASS trial proved that celecoxib is safer
to gastrointestinal tract in comparison to non-selective COX
inhibitors [10].
Cardiorenal safety of celecoxib compared to ibuprofen
according to the doses used in the CLASS trial is used in this
study.
1.1. Aim of the Work. The purpose of this study was to
examine the Cardiorenal eﬀects of a representative agent
from diﬀerent classes of NSAIDs; celecoxib represent the
selective COX inhibitors, and ibuprofen represents the non-
selective COX inhibitors.
2.Subjectsand Methods
2.1.Subjects. This study was conductedon792patientsfrom
the orthopedic outpatient clinics Al-Salam hospital, Jeddah,
Saudia Arabia.
2.2. Inclusion Criteria . Patients with a history of RA or OA
with average of 40–70 years, were divided into 2 groups.
Group I. This group included 396 patient’s administered
celecoxib (selective COX2 inhibitor) at supratherapeutic
dose, that is, 400mg b.i.d. The supratherapeutic dose equals
two- to four-fold greater than the maximum eﬀective doses
for RA and OA.
Group II. This group included 396 patients administered
ibuprofen(non-selective COXinhibitor) attherapeuticdose,
that is, 800mg t.d.s.
The used doses were commonly prescribed and indicated
for use by FDA and CLASS trial.
An institutional review board (IRB) approval was ob-
tainedforthestudy.Informedconsentwasgiventoallpartic-
ipants before enrollment to read and being discussed with
the investigator and staﬀ. All participants signs on informed
consent on entering the study.
After baseline visit and administration of the initial dose
ofstudymedication, followuptookplaceeverytwoweeksfor
two months, and then every 4 weeks thereafter, until study
termination.Allpatientstookstudymedicationfor6months
from October 1st 2006 to April 1st 2007.
2.3. Exclusion Criteria.
(i) underlying peptic ulcer
(ii) history of myocardial infarction
(iii) stroke
(iv) cerebrovascular accident
(v) transient ischemic attack (TIA)
(vi) renal insuﬃciency in 6 months before the study, that
is, serum creatinine above 1.5mg/dL
(vii) any medications that could directly or indirectly af-
fect renal functions.
2.4. Methods. In each visit, each patient in the two groups
was subjected to the follwing:
(1) questionnaires to collect relevant data for, example,
any experienced symptoms that were not associated
with patients’ arthritis since the last visit
(2) careful physical examination with special concern to
the following:
(a) body weight at least ≥3% increase was consid-
ered positive ﬁnding,
(b) vital signs especially blood pressure with record
of the positive cases, that is, increase in systolic
>2 0 m m / H g ,i n c r e a s ei nb a s el i n eo ra b s o l u t e
level above 140mm/Hg, and for diastolic blood
pressure >15mm/Hg, increase in baseline or
absolute level above 90mm/Hg,
(c) edema whether peripheral or generalized by
inspection and palpation through pressing the
skin over the lateral melleolus of the tibia in the
leg,
(d) manifestations of congestive heart failure
(CHF): generalized edema, congested neck
veins, and enlarged tender liver.
(3) laboratory investigations.
Blood samples: in each visit, 25μL of blood were drawn
up from each patient and used to measure the levels of the
following.Journal of Toxicology 3
2.4.1. Blood Urea Nitrogen (BUN). Each case had the BUN
≥20mg/dL deﬁned as mild prerenal azotemia and completes
the other kidney function tests.
Blood urea nitrogen (BUN) was assayed by colorimetric
method described by Patton and Crouch [11]u s i n ga
commercial kit of Bio-Merieux (France). Normal value: 18–
33mg/dL.
2.4.2. Serum Creatinine Level. The aim was to detect any
increase in creatinine level by 0.5mg/dL over baseline or any
value above 1.5mg/dL during the study.
Serum creatinine was assayed by colorimetric method
described by Henry [12] using a commercial kit of Diamond
Diagnostics (Egypt). Normal value: 0.8–2.0mg/dL.
2.4.3. Creatinine Clearance. (as calculated by Cockcroft
Gauntformula) = 140−(age×weight)÷(serum creatinine×
72).
If ≥30% from the baseline during treatment, it should be
analyzed as well [12].
2.4.4. Serum Electrolytes. They included sodium, potassium,
chloride, and bicarbonate [12].
3.StatisticalMethod [13]
The methods used for statistical analysis of the collected data
were the following:
(1) t-test for comparison between the means of two
means ± standard deviations, and P values less
than .05 was considered signiﬁcant,
(2) one-way ANOVA test (F test) for comparison
betweenmorethantwomeans ±standarddeviations.
4.Results
As Figure 1 shows, a total number of 792 patients were
randomized, of whom received at least one dose of the study
drug, and were, therefore, included in the intent-to-treat
(ITT) population (RA: N=290; OA: N=502). In the ITT
population, 396 patients received celecoxib, and 396 were
treated with ibuprofen.
Mean patient’s age was about 55 years in each treatment
group; most (69%–71%) patients were female, and mean
BP was 133/80mm/Hg. As determined by medical history,
slightly less than 40% of patients of each treatment group
had preexisting hypertension. Overall BP levels and renal
function were normal at baseline and comparable between
treatment groups; see (Table 1).
Blood Presuure (Table 2). Celecoxib was associated with an
incidence of hypertension (both new-onset and aggravated)
that was signiﬁcantly lower than standard doses of ibuprofen
(P<. 05). Withdrawals from study treatment owing to
hypertension-related adverse events were uncommon and
occurred with similar frequency among the two treatment
Table 1: Baseline characteristics and exposure to treatment.
Celecoxib
400mg b.i.d.
(N=396)
Ibuprofen
800mg t.d.s.
(N=396)
Exposure to treatment
median (days) 182 176
Age
Mean (years) 55.2 54.9
60–70 years (%) 26.6 25.5
≥70 years (%) 5.2 3.9
Female 68.5 70.8
History (%)
Hypertension 39.0 38.1
Diabetes 8.8 8.1
Creatinine
Serum level (mg/dL) 0.79 0.77
Clearance (mL/min.)∗ 112.2 116.4
b.i.d. twice a day; t.d.s. three times a day.
∗estimated by Cockroft-Gault formula.
Table 2: Blood pressure eﬀects of celecoxib versus ibuprofen.
Event
Celecoxib
400mg b.i.d.
(N=396)
Ibuprofen
800mg t.d.s.
(N=396)
Any hypertension adverse event (%
of patients)§ 2.7 4.2∗
New-onset hypertension (% of
patients) 2.0 3.1∗
Aggravated hypertension (% of
patients) 0.8 1.2
Withdrawal for hypertension
related adverse eﬀects (% of
patients)§
0.3 0.3
Mean change in blood pressure
(mmHg)
Systolic −0.6 >20∗
Diastolic −0.7 3.2
Increases in blood pressure (% of
patients)#
Systolic >20mmHg from baseline
and absolute value > 140mmHg 5.0 7.0∗
Diastolic >15mmHg from baseline
and absolute value > 90mmHg 1.9 2.2
b.i.d. twice a day; t.d.s. three times a day.
§New-onset or aggravated.
#observed at ﬁnal clinicvisit.
∗P <.05 versus celecoxib by Fisher exact test.
groups. In patients taking ibuprofen, the increased incidence
of hypertension versus celecoxib was accompanied by a
corresponding trend towards a mean increase in systolic BP
(P = .09).
Ibuprofen treatment was associated with a signiﬁcantly
(P<. 05) greater proportion of patients with systolic
elevation >20mm/Hg and above 140mm/Hg as compared4 Journal of Toxicology
N = 792
patients taking study
medication
N = 396
celecoxib 400mg b.i.d.
N = 396
ibuprofen 800mg t.d.s.
N = 370
completed study
N = 366
completed study
N = 26 withdrawn N = 30 withdrawn
Adverse event:12; non
compliance: 6
treatment failure:8
Adverse event:12; non
compliance: 8
treatment failure:10
Figure 1: patient disposition in the study. Of 792 patients randomized and took study medication (ITT cohort), 736 patients completed the
study. The most common reason for withdrawal from the trial was an adverse event, followed by lack of drug eﬃcacy and non-compliance
with the protocol.
Creatinine
clearance
Serum
creatinine
Celecoxib
Ibuprofen
0
20
40
60
80
100
M
e
a
n
c
h
a
n
g
e
i
n
l
e
v
e
l
Figure 2: Renal eﬀects of celecoxib versus ibuprofen.
with celecoxib. No treatment diﬀerences were observed for
diastolic BP.
Fluid Retention (Table 3). Ceceloxib was associated with
signiﬁcantly lower incidence of investigator-reported edema
(includingeitherperipheralorgeneralizededema)compared
with ibuprofen (P<. 05) (see Figure 2).
Adverse events of CHF were uncommon as reported by
investigators (approximately one-tenth the rate of overall
edema, and no signiﬁcant diﬀerences were detected between
treatments). Withdrawals from study treatment owing to
either edema or CHF were uncommon overall, and no
signiﬁcant treatment-related diﬀerences were detected. In
addition, no signiﬁcant treatment diﬀerences were observed
with respect to body weight gain ≥3%.
Renal Functions. Renal functions of enrolled patients were
normal, as reﬂected by baseline serum creatinine levels
or estimated creatinine clearance; see (Table 1). Nearly all
patients (>99%) had a serum creatinine ≤1.5mg/dL, which
reﬂect normal function required for protocol.
Renal functions, as reﬂected by serum creatinine levels
and estimated creatinine clearance, decreased signiﬁcantly in
patientsassignedtoibuprofencomparedwiththosereceiving
celecoxib (P<. 05) (Table 4).
Clinically important renal dysfunction, deﬁned as (1)
increases in serum creatinine > 0.5mg/dL relative to baseline
assessment or serum creatinine >1.5mg/dL atany post-base-
line assessment or (2) a decrease in estimated creatinine
clearance ≥30% relative to baseline are provided in.
Fortheentiretreatmentcohort,onesigniﬁcanttreatment
diﬀerence was detected: the incidence of ≥30% reductionsJournal of Toxicology 5
in estimated creatinine clearance from baseline was signiﬁ-
cantly lower in treatment with celecoxib as compared with
ibuprofen (Table 5).
An evaluation of the time course of these changes
revealed that the highest frequency occurred early after
initiation of treatment (week 4 and 8 clinic visits) and de-
clined thereafter, rather than progressively increasing risk as
a function of duration of treatment of the two treatment
g r o u p s .I ts h o u l db en o t e d ,h o w e v e r ,t h a tas u b s t a n t i a lp r o -
portion of patients exhibited these changes 3 months or
longer after treatment was initiated, suggesting that the haz-
ard, although perhaps diminishing with time, does continue
through the therapy period. Increases in serum creatinine of
>0.1mg/dL were uncommon, occurring in seven celecoxib-
treated patients and nine patients taking ibuprofen. These
diﬀerenceswere not signiﬁcantly diﬀerent.Forthose patients
characterized by mild prerenal azotemia at baseline (serum
blood urea nitrogen >20mg/dL) but relatively normal renal
functions; see (Table 5), the incidence of clinically important
changes in renal function was at least two-fold lower
(P<. 05) in patients receiving ceclecoxib compared with
ibuprofen-treated patients.
Treatment diﬀerences in mean serum creatinine and
estimated creatinine clearance were also observed in this
cohort; see (Table 5). No diﬀerences were observed between
treatmentgroupsforpatientswithoutbaseline azotemia(i.e.,
with BUN ≤20mg/dL).
Patientswith normal serumcreatinine/prerenal azotemia
at baseline were signiﬁcantly more likely to withdraw from
the study owing to an adverse event if their creatinine level
increased to >1.5mg/dL on treatment versus the overall
cohort (relative risk, 2.0; P<. 05). When expressed
as percentage of the patients with normal serum creati-
nine/prerenal azotemia at baseline, the withdrawal rate in
patientstreated with celecoxib(1.5%)was signiﬁcantly lower
compared with those receiving ibuprofen (4.2%; P<. 05) as
shown in Figure 3.
ElectrolyteandAcidBase. Changesinserumlevelsofsodium,
potassium, chloride, and bicarbonate were minimal between
treatment groups and were not of clinical signiﬁcance.
Serious Cardiorenal-Related Adverse Events. The incidenceof
serious cardiorenal-related adverse events during treatment
with celecoxib or ibuprofen was low. The study investigator
reported one case of uremia in an ibuprofen-treated patient.
Two cases of hyponatremia were reported in patients treated
with celecoxib, and one case was reported in a patient
taking ibuprofen. No cases of serious adverse events related
to nephrotic syndrome, interstitial nephritis, or papillary
necrosis were observed.
5.Discussion
The large cardiorenal database from the CLASS trial pro-
vided the opportunity to observe and compare the natural
history of the onset and clinical management of cardiorenal
related adverse events that evolve when exposing a typical
Table 3: Fluid retention eﬀects of celecoxib versus ibuprofen.
Celecoxib
400mg b.i.d.
(N=396)
Ibuprofen
800mg t.d.s.
(N=396)
Any edema-related
adverse events (% of
patients)§
4.1 6.2∗
CHF Congestive Heart
Failure (% of patients) 0.5 0.5
Withdrawals for
edema-related adverse
events (% of patients)
0.7 1.0
Withdrawals due to CHF
(% of patients) 0.1 0.3
Increase in body weight
of ≥3% (% of patients) 20.7 21.1
b.i.d. twice a day; t.d.s. three times a day.
§Includesinvestigatorreportsofedema,generalizededemaorperipheral
edema.
∗P<. 05 versus celecoxib by Fisher exact test.
Table 4: Renal eﬀects of celecoxib versus ibuprofen.
Celecoxib
400mg b.i.d.
(N=396)
Ibuprofen
800mg t.d.s.
(N=396)
Mean change in serum
creatinine (mg/dL) 0.009 ± 0.002 0.027 ± 0.004∗
Mean change in
estimated creatinine
clearance (ml/min)
0.08 ± 0.37 −2.82 ± 0.51∗
b.i.d. twice a day; t.d.s. three times a day.
∗P<. 05 versus celecoxib by Fisher exact test.
adult arthritic population to chronic treatment with non-
selective NSAIDs (ibuprofen) or supratherapeutic doses of
COXIB (celecoxib) [14]. Thus, this study provides a new
and important clinical resource of therapeutic cardiorenal
safety information. The data have permitted the description
of a clinical paradigm, where in certain key patient charac-
teristics, it may provide additional predictive clinical infor-
mation with respect to future drug-speciﬁc susceptibility to
impairment of cardiorenal function.
Thepresentanalysissupportthehypothesisthatrheuma-
toid arthritis (RA) and osteoarthritis (OA) patients receiving
celecoxib 400mg b.i.d. have an overall reduced risk of
cardiorenal-related adverse events compared with standard
therapeutic doses of the nonselective NSAIDs, ibuprofen
800mg t.d.s. In particular, celecoxib treatment was superior
to the nonselective NSAIDs with respect to renal function
in patients with prerenal compromise. Some important
diﬀerences were observed in the cardiorenal safety proﬁles
of celecoxib versus nonselective NSAIDs. Compared with
celecoxib, the incidence of adverse events related to hyper-
tension and edema was signiﬁcantly higher with ibuprofen,
and the decline in renal functions was also more apparent
with ibuprofen. These data provide a greater understanding6 Journal of Toxicology
Celecoxib
Ibuprofen
Celecoxib
Ibuprofen
Figure 3: Whithdrawal form the study due to adverse event.
Table 5: Renal functions in patients with prerenal azotemia at
baseline (BUN > 20mg/dL).
Comparison item
Celecoxib
400mg b.i.d.
(N=126)
Of total 396
Ibuprofen
800mg t.d.s
(N=146)
Of total 396
Baseline serum
creatinine (mg/dL) 0.93 0.94
Estimated baseline
creatinine clearance
(mg/dL)
91.1 91.3
Mean change in serum
creatinine (mg/dL) 0.003 ± 0.007 0.049 ± 0.012∗
Mean change in
estimated creatinine
clearance (ml/min.)
1.27 ± 0.69 −1.65 ± 1.03∗
Withdrawal of study
owing to adverse event 1.5 4.2∗
b.i.d. twice a day; t.d.s. three times a day; BUN: blood urea nitrogen.
∗P<. 05 by analysis covariance by Fisher exact test.
of the relative eﬀects of these agents on cardiorenal function
and homeostasis.
The increased incidence of hypertension in patients
taking ibuprofen versus celecoxib appeared to be largely
af u n c t i o no fe ﬀects on systolic, rather than diastolic, BP.
Ibuprofenwasassociated with signiﬁcantly higherincidences
of clinically meaningful elevations in systolic BP versus cele-
coxib. The importance of systolic BP has been highlighted
in ALLAHT [15], Kostis et al. [16], and Steassen et al. [17].
These studies showed that elevated systolic BP is associated
with heart failure, stroke, myocardial infarction, and death.
Whelton et al. [18] evidenced now that destabilization of
BP in treated hypertensive patients, by rofecoxib, is a signif-
icant risk marker for the development of acute myocardial
infarction and stroke events. Much additional information
with respect to the latter issues and the emergence that some
NSAIDs may also cause cardiotoxicity is needed [19].
In the present study, longterm treatment with suprather-
apeutic doses of celecoxib in the CLASS trial had a little
eﬀect on BP levels in these arthritis patients. This ﬁnding is
supported by previous studies demonstrating that celecoxib
does not aﬀect mean systolic BP changes in hypertensive
patients [20, 21].
In contrast, many NSAIDs and COXIBs, such as rofe-
coxib, antagonize the BP-lowering eﬀects of certain anti-
hypertensive agents, in particular, angiotensin-converting
enzyme inhibitors and β-blockers [22].
In the present analysis, celecoxib was superior to the
ibuprofen studied with respect to renal dysfunction. Ibupro-
fen appeared to cause a signiﬁcantly higher rate of decline in
renal functions than celecoxib.This maysuggesta dispropor-
tionate eﬀect of ibuprofen on renal perfusion. Importantly,
in patients with prerenal azotemia (but normal serum creat-
inine) at baseline, celecoxib was associated with a lower-rate
deterioration of renal functions compared with ibuprofen.
However, as some renal dysfunction was evident in the
celecoxib treatment group, caution should still be used when
treating patients at risk of adverse renal events. Changes
in electrolytes levels were small and were not of clinical
relevance.
In healthy human subjects on normal diets, COX-2
inhibitors have minimal eﬀects on renal hemodynamics [23,
24] that COX-2 inhibitors decrease GFR in salt-depleted
subjects [25–27]. Since nitric oxide (NO) regulates renal
cortical COX-2 expression [28], Lopez et al. [29]p r o p o s e d
that in addition to the salt depletion and prolonged duration
of COX-2 inhibition, reduced NO may be another factor
underlyingtheseeﬀectsofCOX-2-speciﬁcinhibitorsonrenal
hemodynamic.
It is evident from this study that there are diﬀerential
cadiorenal eﬀects associated with celecoxib versus nonselec-
tive NSAIDs, ibuprofen. Previous studies have also shown
that cadiorenal safety proﬁles are not consistent across the
class of COXIBs. For example, rofecoxib treatment is asso-
ciated with dose-dependent increases in hypertension and
edema [30–32].
Intworecent,randomizeddouble-blindtrialsfor6weeks
of OA patients taking antihypertensive agents, the study
participants taking celecoxib 200mg daily were less likely
to experience renal adverse events than the group receiving
rofecoxib 25mg daily [33].
The diﬀering renal safety proﬁles across the classes of
nonselective NSAIDs and COXIBs suggest that some of the
renal eﬀects of the latter may be “molecule-speciﬁc” rather
than as a result of a “class eﬀect” of COX-2 inhibition [34].
This study suggested that the clinical management of
arthritis patients may be impacted by the agent selected to
treat their pain and by the patient’s underlying health status
with regard to cadiorenal side eﬀects. Our results indicate
that cadiorenal side eﬀects are relatively common with
NSAID treatment and require careful medical monitoring
of patients together with other safety-related parameters
(e.g., hepatotoxicity associated with some NSAIDs such as
diclofenac).Journal of Toxicology 7
Anti-inﬂammatory drug-induced eﬀects on BP or renal
function should be cautiously monitored clinically during
the use of such drugs. These adverse renal events may be
selectively reduced or minimized by the selection of an anti-
inﬂammatory drug, such as celecoxib, that appears to have
the least detrimental eﬀects upon renal function, such as
demonstrated in this study.
The present analysis had some potential limitations.
Many OA and RA patients were elderly and had signiﬁcant
comorbidity, including cardiovascular disease, hypertension,
and abnormal renal functions. However, our study did not
include patients with abnormal renal functions at baseline,
and results could not apply to these patients. Another
limitation in the present analysis was that patients in this
s t u d yw e r en o ts t r a t i ﬁ e db yb a s e l i n eb o d yw e i g h t ,w h i c hm a y
impact signiﬁcantly on baseline creatinine levels.
6.Conclusion
Supratherapeutic dose of celecoxib was associated with a
cardiorenal safety proﬁle compared with standard doses of
ibuprofen.
7.Recommendations
(1) Further work is needed to study the renal safety pro-
ﬁle of nonspeciﬁc NSAIDs and COXIBs in patients
with abnormal renal function.
(2) Physicians need to be alerted to eﬀects of NSAIDson
BP and kidney functions.
(3) Celecoxib should be given to arthritic patients with
prerenal azotemia and classic NSAIDs should be
avoided.
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